Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Evonik.

  • Webinars & Exhibitions

  • Oral Technologies

  • CMO for Controlled Substances

  • Microbial Fermentation

  • API Contract Manufacturing

  • Development of High Potency APIs (HPAPIs)

  • Chiral Synthesis

  • Drug Delivery Technology

  • Hot Melt Extrusion

  • Coating Technology

PharmaCompass
Evonik
Evonik
Germany Flag
Country
Country
Germany
Address
Address
Rellinghauser Straße 1-11, Essen, NRW 45128, DE
Telephone
Telephone
+49 20117701
Contact Info
Others

left grey arrow
right gray arrow

Details:

ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.


Lead Product(s): Bupivacaine

Therapeutic Area: Neurology Product Name: ATX-101

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Allay Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 13, 2022

Details:

Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.


Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Triple Pack

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Phathom Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 24, 2022

Details:

Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell, where it is released.


Lead Product(s): mRNA-based Therapy

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Large molecule

Partner/Sponsor/Collaborator: BARDA

Deal Size: $220.0 million Upfront Cash: Undisclosed

Deal Type: Funding June 02, 2022

Details:

Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.


Lead Product(s): Simufilam

Therapeutic Area: Neurology Product Name: PTI-125

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Cassava Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 09, 2021

Details:

Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership between Evonik and the Comirnaty, vaccine manufacturer BioNTech.


Lead Product(s): Tozinameran

Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty

Highest Development Status: ApprovedProduct Type: Vaccine

Partner/Sponsor/Collaborator: BioNTech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 11, 2021

Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY